Since FDG is the tracer to detect inflammation, the researchers estimate, based on initial trials, that making FDT will add only 25% to 50% to the cost of FDG, inversely scaling with the dose as the additional costs become a smaller fraction, according to Davis.

The team's long-term goal is to both distribute the plasmids for the enzymes to enable local fermented production and to establish local "at cost" production models that can “piggyback off widespread biochemical knowledge without the need for specialist radiochemistry skills,” Davis said.


"There is the additional possibility of ... international distribution of enzymes and we are currently investigating the models for minimal cost transport models, i.e., non-cold chain distribution of enzyme ‘powders’ that would be reactivated on dissolution at site," Davis said. "The latter would simply require the correct buffers and a source of FDG."

The team, funded by the Gates Foundation and UK Research and Innovation, recently published their preclinical research in Nature Communications. A Phase I trial has not yet been scheduled.

Back to HCB News

Molecular Imaging Homepage